Immunogenicity and safety of an Entamoeba histolytica adjuvanted protein vaccine candidate (LecA+GLA-3M-052 liposomes) in rhesus macaquesHUMAN VACCINES & IMMUNOTHERAPEUTICSIF3.52024-08-011OAAI
Semi-synthetic terpenoids with differential adjuvant properties as sustainable replacements for shark squalene in vaccine emulsionsNPJ VACCINESIF6.52023-02-1612OAAI
Intranasal delivery of a synthetic Entamoeba histolytica vaccine containing adjuvant (LecA + GLA-3 M-052 liposomes): In vitro characterizationINTERNATIONAL JOURNAL OF PHARMACEUTICSIF5.22022-10-014OAAI
Optimizing a Multi-Component Intranasal Entamoeba Histolytica Vaccine Formulation Using a Design of Experiments StrategyFRONTIERS IN IMMUNOLOGYIF5.92021-06-2515OAAI
Control of Heterologous Simian Immunodeficiency Virus SIVsmE660 Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in MacaquesJOURNAL OF VIROLOGYIF3.82018-08-0131OAAI
A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7JOURNAL OF NANOBIOTECHNOLOGYIF12.62014-04-2684OAAI
Modulating Potency: Physicochemical Characteristics are a Determining Factor of TLR4-Agonist Nanosuspension ActivityJOURNAL OF PHARMACEUTICAL SCIENCESIF3.82014-03-0110PREAI
Optimizing manufacturing and composition of a TLR4 nanosuspension: physicochemical stability and vaccine adjuvant activityJOURNAL OF NANOBIOTECHNOLOGYIF12.62013-12-2116OAAI
Charged aerosol detection to characterize components of dispersed-phase formulationsADVANCES IN COLLOID AND INTERFACE SCIENCEIF19.32013-11-018PREAI
Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosisJOURNAL OF CONTROLLED RELEASEIF11.52013-11-0198OAAI